ZEAL Stock Overview
A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Zealand Pharma A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | DKK 871.50 |
52 Week High | DKK 972.00 |
52 Week Low | DKK 252.60 |
Beta | 0.64 |
11 Month Change | -4.75% |
3 Month Change | 36.28% |
1 Year Change | 239.37% |
33 Year Change | 318.59% |
5 Year Change | 445.03% |
Change since IPO | 996.23% |
Recent News & Updates
Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade
Aug 21Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 18Recent updates
Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade
Aug 21Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 18Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)
Mar 17Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation
Oct 03Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term
Aug 14Some Zealand Pharma A/S (CPH:ZEAL) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 14Is Zealand Pharma's (CPH:ZEAL) 113% Share Price Increase Well Justified?
Mar 11What You Need To Know About Zealand Pharma A/S' (CPH:ZEAL) Investor Composition
Jan 12Shareholder Returns
ZEAL | DK Biotechs | DK Market | |
---|---|---|---|
7D | -1.5% | 1.2% | 0.5% |
1Y | 239.4% | 2.4% | 28.4% |
Return vs Industry: ZEAL exceeded the Danish Biotechs industry which returned -0.1% over the past year.
Return vs Market: ZEAL exceeded the Danish Market which returned 25.1% over the past year.
Price Volatility
ZEAL volatility | |
---|---|
ZEAL Average Weekly Movement | 8.7% |
Biotechs Industry Average Movement | 7.3% |
Market Average Movement | 4.4% |
10% most volatile stocks in DK Market | 9.1% |
10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: ZEAL's share price has been volatile over the past 3 months.
Volatility Over Time: ZEAL's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 288 | Adam Steensberg | www.zealandpharma.com |
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Zealand Pharma A/S Fundamentals Summary
ZEAL fundamental statistics | |
---|---|
Market cap | DKK 61.82b |
Earnings (TTM) | -DKK 712.00m |
Revenue (TTM) | DKK 367.97m |
168.0x
P/S Ratio-86.8x
P/E RatioIs ZEAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ZEAL income statement (TTM) | |
---|---|
Revenue | DKK 367.97m |
Cost of Revenue | DKK 714.45m |
Gross Profit | -DKK 346.47m |
Other Expenses | DKK 365.53m |
Earnings | -DKK 712.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | -10.04 |
Gross Margin | -94.16% |
Net Profit Margin | -193.49% |
Debt/Equity Ratio | 2.9% |
How did ZEAL perform over the long term?
See historical performance and comparison